These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31754235)

  • 1. Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells.
    Wang Z; Geng Z; Shao W; Liu E; Zhang J; Tang J; Wang P; Sun X; Xiao L; Xu W; Zhang Y; Cui H; Zhang L; Yang X; Chang X; Qiu X
    Cell Mol Immunol; 2020 Nov; 17(11):1148-1162. PubMed ID: 31754235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
    Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
    Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.
    Egan H; Treacy O; Lynch K; Leonard NA; O'Malley G; Reidy E; O'Neill A; Corry SM; De Veirman K; Vanderkerken K; Egan LJ; Ritter T; Hogan AM; Redmond K; Peng L; Che J; Gatlin W; Jayaraman P; Sheehan M; Canney A; Hynes SO; Kerr EM; Dunne PD; O'Dwyer ME; Ryan AE
    Cell Rep; 2023 May; 42(5):112475. PubMed ID: 37167967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tools to study and target the Siglec-sialic acid axis in cancer.
    Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
    FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
    Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
    Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.
    Büll C; Boltje TJ; Balneger N; Weischer SM; Wassink M; van Gemst JJ; Bloemendal VR; Boon L; van der Vlag J; Heise T; den Brok MH; Adema GJ
    Cancer Res; 2018 Jul; 78(13):3574-3588. PubMed ID: 29703719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
    Benmerzoug S; Chevalier MF; Verardo M; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
    Eur Urol Focus; 2022 May; 8(3):748-751. PubMed ID: 34147404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.
    Gianchecchi E; Arena A; Fierabracci A
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
    Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
    J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
    Wieboldt R; Sandholzer M; Carlini E; Lin CW; Börsch A; Zingg A; Lardinois D; Herzig P; Don L; Zippelius A; Läubli H; Mantuano NR
    Cell Mol Immunol; 2024 May; 21(5):495-509. PubMed ID: 38448555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic potential of sialylated Fc domains of human IgG.
    Pleass RJ
    MAbs; 2021; 13(1):1953220. PubMed ID: 34288809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl- to N-acetyl-neuraminic acid and generation of ligands for siglec-E.
    Redelinghuys P; Antonopoulos A; Liu Y; Campanero-Rhodes MA; McKenzie E; Haslam SM; Dell A; Feizi T; Crocker PR
    J Biol Chem; 2011 Oct; 286(40):34522-32. PubMed ID: 21835922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Siglec-9 Regulates an Effector Memory CD8
    Haas Q; Boligan KF; Jandus C; Schneider C; Simillion C; Stanczak MA; Haubitz M; Seyed Jafari SM; Zippelius A; Baerlocher GM; Läubli H; Hunger RE; Romero P; Simon HU; von Gunten S
    Cancer Immunol Res; 2019 May; 7(5):707-718. PubMed ID: 30988027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation.
    Käsermann F; Boerema DJ; Rüegsegger M; Hofmann A; Wymann S; Zuercher AW; Miescher S
    PLoS One; 2012; 7(6):e37243. PubMed ID: 22675478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sialylation pattern in lung epithelial cell line and Siglecs expression in monocytic THP-1 cells as cellular indicators of cigarette smoke - induced pathology in vitro.
    Wielgat P; Trofimiuk E; Czarnomysy R; Holownia A; Braszko JJ
    Exp Lung Res; 2018 Apr; 44(3):167-177. PubMed ID: 29781747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
    van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
    Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation.
    MacMillan HF; Lee T; Issekutz AC
    Clin Immunol; 2009 Aug; 132(2):222-33. PubMed ID: 19447680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting sialylation to treat central nervous system diseases.
    Lünemann JD; von Gunten S; Neumann H
    Trends Pharmacol Sci; 2021 Dec; 42(12):998-1008. PubMed ID: 34607695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
    Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
    Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.